Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment
NCT06104280
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Opioid use disorder (OUD) is a treatable medical illness with three medications FDA approved for treatment. However, persons with OUD report significant sleep disturbance, even when treated with medications for opioid use disorder, leading to high rates of relapse. In this project, we will investigate a special set of photosensitive neurons in the retina as an underlying mechanism for circadian rhythm and sleep disturbance from opioid use and medications for OUD that could lead to novel intervention and improve treatment outcomes.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Opioid Use Disorder
- Sleep Disturbance
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- University of Alabama at Birmingham
- Last updated on ClinicalTrials.gov
- August 11, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- University of Alabama at Birmingham · Birmingham, AL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.